Teva stock drops 13% as Tel Aviv trade begins

Teva lost due to new competition as Mylan N.V just got the green light to start selling its' own version of Copaxone.

October 8, 2017 10:29
1 minute read.
Teva stock drops 13% as Tel Aviv trade begins

A building in Jerusalem belonging to generic drug producer Teva. (photo credit: REUTERS/BAZ RATNER)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Teva stock lost 13% value Sunday morning as the Israeli stock market began trading. Sunday's drop comes as Teva is on the ropes  due to new competition. 

Teva suffered a major blow as pharmaceutical rival Mylan N.V. reported after close of trade on October 4'th that the US Food and Drug Administration (FDA) had approved its generic versions of Copaxone, a major Teva seller. 

Be the first to know - Join our Facebook page.

Mylan said that the FDA had approved its 20 mg. daily injection version of the multiple sclerosis treatment and its 40 mg three times weekly version and that it can begin marketing imminently.

Copaxone is Teva's flagship branded drug. Sales reached nearly $2 billion in the first half of 2017 with estimated profits of $1.5 billion.

Copaxone's price has risen 1,002% since it was launched in 1996, and the price of the 40 mg version has risen 30% since it was launched in 2014.

In premarket trading on Wall Street, Teva's share price was down 15.25% at $15.94.

Teva warned that any launch by Mylan of a generic version of Copaxone 40mg prior to final resolution of the pending patent appeals and other patent litigation should be considered an “at-risk” launch, which could subject Mylan to significant damages among other remedies.

“We have planned for the eventual introduction of a generic competitor to glatiramer acetate,” said Dr. Yitzhak Peterburg, Teva’s Interim president and CEO. “We remain confident in patient and physician loyalty to Teva’s Copaxone due to its recognized efficacy, safety and tolerability profile, and we will continue to promote and support the product. As we are closing the third quarter, it is too soon to officially comment on any change to our full year business outlook.”
Drugmaker Teva hires new CEO to restore its health, September 11, 2017. (Reuters)

Due to the anticipated launch of another generic 20mg glatiramer acetate product and the anticipated launch of a first generic 40mg glatiramer acetate product, Teva’s early assessment of the impact of these launches to its earnings for the fourth quarter ended December 31, 2017 is that it could be affected by at least $0.25 cents per share.

Related Content

July 21, 2018
Syrian regime pounds ISIS near Golan